South Korea · Health Care · KRW (Millions) · Annual
Key financials
KRW|Millions
ROE
-127.09%
2025 (actual)
ROA
-33.43%
2025 (actual)
Gross Margin
25.51%
2025 (actual)
Net Margin
-118.48%
2025 (actual)
Total Assets
₩92,713.95M
2025 (actual)
Net Income
-₩31,951.04M
2025 (actual)
Valuation
₩185,978.37M
2026 (forecast)
Stock Price
₩3,910
Historical & projected performance
KRW|Millions
Reported figures and Equlion model projections for the next 5 years.
ROE
+165.4 pt
Company
ROA
-30.9 pt
Company
Gross Margin
-4.6 pt
Company
Sector average
Net Margin
-18.8 pt
Company
Total Assets
+66.7%
Company
Sector average (own scale)
Net Income
-201.4%
Company
Sector average (own scale)
Valuation
+153.9%
Company
Sector average
Stock Price
+153.9%
Company
Sector average (own scale)
Amounts in KRW (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.
Want the full financial forecast report for T&R Biofab Co., Ltd.? It covers the balance sheet, income statement, cash flow and Equlion model projections.